Implantable defibrillators in cardiac amyloidosis

International Journal of Cardiology

Volumn 165, Issue 2, 2013, Pages 371-373

  Van Galen, Karin P M ^a   Van Dijk, Jeroen ^b   Regelink, Josien C ^b   Huijgens, Peter C ^b   Minnema, Monique C ^a   Zweegman, Sonja ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiac amyloidosis; Implantable cardioverter defibrillator; Sudden death

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; TROPONIN; BORTEZOMIB;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; FAINTNESS; FEMALE; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HEMODIALYSIS; HOLTER MONITORING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LETTER; MALE; PRIORITY JOURNAL; PROGNOSIS; QT INTERVAL; TACHYCARDIA; TELEMETRY; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; HEART VENTRICLE TACHYCARDIA; IMPLANTATION; LOW RISK PATIENT; PREDICTION; PROSPECTIVE STUDY; QT PROLONGATION; REMISSION; RESUSCITATION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SUDDEN DEATH; SURVIVAL; SURVIVAL RATE; SYMPTOM; THERAPY EFFECT;

EID: 84876692809     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.08.028     Document Type: Article

References (33)

1. R.A. Kyle, and P.R. Greipp Amyloidosis (AL). Clinical and laboratory features in 229 cases Mayo Clin. Proc. 58 10 1983 Oct 665 683
2. S.W. Dubrey, K. Cha, and J. Anderson The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement QJM 91 2 1998 Feb 141 157
3. G. Palladini, and G. Merlini Current treatment of AL amyloidosis Haematologica 94 8 2009 Aug 1044 1048
4. M.T. Cibeira, V. Sanchorawala, and D.C. Seldin Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients Blood 118 16 2011 Oct 20 4346 4352
5. H.M. Lokhorst, B.P. Hazenberg, and A. Croockewit High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N. Engl. J. Med. 358 1 2008 Jan 3 92 93
6. S. Madan, S.K. Kumar, and A. Dispenzieri High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement Blood 119 5 2012 Feb 2 1117 1122
7. E. Kastritis, A.D. Wechalekar, and M.A. Dimopoulos Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis J. Clin. Oncol. 28 6 2010 Feb 20 1031 1037
8. C.P. Venner, T. Lane, and D. Foard Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Blood 119 19 2012 May 10 4387 4390
9. S. Dietrich, S.O. Schonland, and A. Benner Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement Blood 116 4 2010 Jul 29 522 528
10. A. Jaccard, P. Moreau, and V. Leblond High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N. Engl. J. Med. 357 11 2007 Sep 13 1083 1093
11. G.H. Bardy, K.L. Lee, and D.B. Mark Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N. Engl. J. Med. 352 3 2005 Jan 20 225 237
12. H. Mlcochova, W.I. Saliba, and D.J. Burkhardt Catheter ablation of ventricular fibrillation storm in patients with infiltrative amyloidosis of the heart J. Cardiovasc. Electrophysiol. 17 4 2006 Apr 426 430
13. A. Dhoble, A. Khasnis, A. Olomu, and R. Thakur Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review Clin. Cardiol. 32 8 2009 Aug E63 E65
14. E.P. Hess, and R.D. White Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients Resuscitation 60 1 2004 Jan 105 111
15. M. Itoh, K. Ohmori, and K. Yata Implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis Am. J. Hematol. 81 7 2006 Jul 560 561
16. G. Lin, A. Dispenzieri, and P.A. Brady Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death Eur. Heart J. 31 12 2010 Jun 1538
17. S. Seethala, S. Jain, and N.P. Ohori Focal monomorphic ventricular tachycardia as the first manifestation of amyloid cardiomyopathy Indian Pacing Electrophysiol. J. 10 3 2010 143 147
18. B.L. Wright, A.A. Grace, and H.J. Goodman Implantation of a cardioverter-defibrillator in a patient with cardiac amyloidosis Nat. Clin. Pract. Cardiovasc. Med. 3 2 2006 Feb 110 114
19. H. Yaoita, M. Iwai-Takano, and K. Ogawa Attenuation of diastolic heart failure and life-threatening ventricular tachyarrhythmia after peripheral blood stem cell transplantation combined with cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis Circ. J. 72 2 2008 Feb 331 334
20. R.H. Falk, K. Monahan, and T. Smith Failure of the implantable defibrillator to prevent sudden death in cardiac amyloidosis Circulation 102 18 2000 Oct 31 396
21. A.V. Kristen, T.J. Dengler, and U. Hegenbart Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death Heart Rhythm 5 2 2008 Feb 235 240
22. W.C. Levy, K.L. Lee, and A.S. Hellkamp Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population Circulation 120 10 2009 Sep 8 835 842
23. D.P. Zipes, A.J. Camm, and M. Borggrefe ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol. 48 5 2006 Sep 5 e247 e346
24. G. Merlini CyBorD: stellar response rates in AL amyloidosis Blood 119 19 2012 May 10 4343 4345
25. G. Palladini, G. Malamani, and F. Co Holter monitoring in AL amyloidosis: prognostic implications Pacing Clin. Electrophysiol. 24 8 Pt 1 2001 Aug 1228 1233
26. Y.B. Goldsmith, J. Liu, J. Chou, J. Hoffman, R.L. Comenzo, and R.M. Steingart Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring Am. J. Cardiol. 104 7 2009 Oct 1 990 994
27. F.I. Parthenakis, P.E. Vardas, L. Ralidis, A. Dritsas, and P. Nihoyannopoulos QT interval in cardiac amyloidosis Clin. Cardiol. 19 1 1996 Jan 51 54
28. S.W. Dubrey, S. Bilazarian, M. LaValley, J. Reisinger, M. Skinner, and R.H. Falk Signal-averaged electrocardiography in patients with AL (primary) amyloidosis Am. Heart J. 134 6 1997 Dec 994 1001
29. J. Reisinger, S.W. Dubrey, M. LaValley, M. Skinner, and R.H. Falk Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement J. Am. Coll. Cardiol. 30 4 1997 Oct 1046 1051
30. A. Dispenzieri, M.A. Gertz, and R.A. Kyle Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J. Clin. Oncol. 22 18 2004 Sep 15 3751 3757
31. A. Dispenzieri, R.A. Kyle, and M.A. Gertz Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins Lancet 361 9371 2003 May 24 1787 1789
32. A. Dispenzieri, M.A. Gertz, and R.A. Kyle Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 104 6 2004 Sep 15 1881 1887
33. G. Palladini, C. Campana, C. Klersy, A. Balduini, G. Vadacca, V. Perfetti, S. Perlini, L. Obici, E. Ascari, G.M. d'Eril, R. Moratti, and G. Merlini Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis Circulation 107 19 2003 May 20 2440 2445